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Strengthening clinical cancer research in the United Kingdom
M Stead*,1,2,14, D Cameron2,3,15, N Lester1,2,16, M Parmar4,5, R Haward2,17, R Kaplan2,17, T Maughan6,7,18,
R Wilson8,19, H Campbell9,20, R Hamilton9,21, D Stewart1,10,16, L O’Toole11,22, D Kerr12,13,23, V Potts1,16,
R Moser2,17, J Darbyshire1,5,16 and P Selby1,2,24 on behalf of the clinicians, research support staff and patients
involved in the National Cancer Research Networks across the UK
1National Institute for Health Research Clinical Research Network Coordinating Centre, Leeds, UK; 2National Cancer Research Network Coordinating
Centre, Leeds, UK; 3Department of Oncology, University of Edinburgh, Edinburgh, UK; 4National Cancer Research Network Coordinating Centre, London,
UK; 5Medical Research Council Clinical Trials Unit, London, UK; 6School of Medicine, Cardiff University, Cardiff, UK; 7Wales Cancer Trials Network
Coordinating Centre, Cardiff, UK; 8N. Ireland Cancer Clinical Trials Unit, Belfast, Northern Ireland; 9Department of Health, England, UK; 10National
Cancer Research Institute, London, UK; 11Arthritis Research UK, London, UK; 12Department of Clinical Pharmacology, University of Oxford, Oxford, UK;
13National Translational Cancer Research Network, Oxford, UK
BACKGROUND: In 1999, 270 000 cases of cancer were registered in the United Kingdom, placing a large burden on the NHS. Cancer
outcome data in 1999 suggested that UK survival rates were poorer than most other European countries. In the same year,
a Department of Health review noted that clinical trials accrual was poor (o3.5% of incident cases) and hypothesised that increasing
research activity might improve outcomes and reduce the variability of outcomes across England. Thus, the National Cancer Research
Network (NCRN) was established to increase participation in cancer clinical research.
METHODS: The NCRN was established in 2001 to provide a robust infrastructure for cancer clinical research and improvements in
patient care. Remit of NCRN is to coordinate, support and deliver cancer clinical research through the provision of research support
staff across England. The NCRN works closely with similar networks in Scotland, Wales and the Northern Ireland. A key aim of
NCRN is to improve the speed of research and this was also assessed by comparing the speed of study delivery of a subset of cancer
studies opening before and after NCRN was established.
RESULTS: Patient recruitment increased through NCRN, with almost 32 000 (12% of annual incident cases) cancer patients being
recruited each year. Study delivery has improved, with more studies meeting the recruitment target – 74% compared with 39%
before NCRN was established.
CONCLUSION: The coordinated approach to cancer clinical research has demonstrated increased accrual, wide participation and
successful trial delivery, which should lead to improved outcomes and care.
British Journal of Cancer (2011) 104, 1529–1534. doi:10.1038/bjc.2011.69 www.bjcancer.com
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In 1999, 270 000 new cases of cancer were registered in the United
Kingdom, placing a large burden on the NHS. Data published in
1999 (Berrino et al, 1999) suggested that survival rates were poorer
in the United Kingdom than in most other European countries.
In the same year, a review by the Department of Health, England
(Cancer Working Group, 1999) noted that accrual into clinical
trials was poor (o3.5% of incident cases) and hypothesised that
increasing research activity might improve outcomes and reduce
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the variability of outcomes across the country. These findings were
instrumental in the establishment of the National Cancer Research
Network (NCRN).
It is accepted that prospective randomised controlled trials
(RCTs), supported by other well-designed clinical studies, provide
the evidence base for the provision of excellent healthcare and the
basis for future developments. The benefits for patients from
participating in clinical research are therefore based substantially
on the provision of an excellent evidence base for high-quality
healthcare. However, there has been considerable discussion about
whether there are benefits from clinical research, which arise other
than from the implementation of the results of high quality trials
and studies. This topic has been reviewed (Braunholtz et al, 2001;
Peppercorn et al, 2004; Vist et al, 2008). There is little convincing
evidence that an individual patient when treated in the context of a
clinical trial within a particular healthcare institution or healthcare
system will have better health outcomes than a similar patient
receiving the same treatment as standard care in the same system.
However, there is stronger support in the literature for the
hypothesis that healthcare systems which are research active rather
than those which are not have better health outcomes perhaps
through the introduction of state-of-the-art care approaches. This
latter question has been addressed in relatively few studies
(Karjalainen and Palva, 1989; du Bois et al, 2005; Majundar et al,
2008), all of which provide supportive evidence.
Here, we provide an overview of the impact of the NCRN and its
UK partner Research Networks since 2001, including a comparison
of study delivery before and after NCRN was established.
MATERIALS AND METHODS
Establishment of NCRN and its Partner Research Networks
NCRN was established in 2001 by the Department of Health,
England and managed by a consortium of the University of Leeds
and the Medical Research Council Clinical Trials Unit. It is now
part of the National Institute for Health Research (NIHR).
The aims of NCRN are to:
 Improve patient care by speeding up access to the best
treatment and care for people in all parts of the country.
 Improve the coordination of research by providing an effective
and efficient mechanism for conducting research in areas that
have been agreed as priorities.
 Improve the speed of research by increasing the numbers of
patients in research and the rate at which they are recruited.
 Maintain and enhance research quality by providing the
processes necessary to develop high-quality research protocols
and the infrastructure necessary to carry them out.
 Widen participation in the research by increasing the number of
NHS organisations, healthcare professionals and patients
participating in research studies.
The initial target was to double the number of adult cancer patients
who entered into clinical research studies in 3 years to 15 000
(7.5%) patients.
The NCRN in England works closely with other cancer research
networks across the United Kingdom, each of which is funded by
its respective health department, and with differing approaches to
the portfolio of trials supported. The Wales Cancer Trials Network,
comprising three Research Networks, was established in 1998.
In 2002, the Scottish Cancer Research Network involving three
Research Networks was established. The Northern Ireland Cancer
Trials Network was established in 2007.
Patients and the public have been actively involved to ensure
that the voice of people affected by cancer helped form, inform and
reform the cancer research.
As part of NCRN, 34 Research Networks were established across
England, each with a Clinical Lead and Network Manager, plus
d200 000 per one-million catchment population. Routine care of
cancer patients was already organised into Cancer Services
Networks that reflected clinical care pathways, and each Research
Network mapped onto these Networks. The organisation of the
Research Networks varies depending on local factors, including
leadership, size, geography, demography and service organisation,
and existing research infrastructure including the presence or
absence of medical schools and teaching hospitals. Wherever
possible, NCRN staff are fully integrated with existing research
staff and with clinical staff in their local Cancer Services Network.
The NCRN has developed into a comprehensive, nationwide,
inclusive organisation, integral to Cancer Services and forming
links with every hospital in the country (from large university
teaching hospitals to small district general hospitals), with growing
links to primary care, and with all disciplines involved in the
research process.
The majority of Network spend is on staffing. There are now
over 750 Network-funded research support staff (528 whole-time
equivalent staff), half of which are Research Nurses.
NCRN has also developed close working relationships with all
organisations involved in the funding, sponsorship and manage-
ment of cancer research – charities, Clinical Trial Units, patient/
public groups and industry.
Comparison of recruitment into studies that closed before
and after NCRN was established
Two groups of non-commercial multicentre RCTs were identified
to compare trial delivery before and after NCRN was established.
The United Kingdom Coordinating Committee on Cancer
Research Trial Register, a comprehensive database of all cancer
RCTs, was searched to identify RCTs that closed before NCRN was
established. The search identified 37 RCTs, of which nine recruited
most patients from non-UK sites and were excluded. The pre-
NCRN group included 28 RCTs that closed between 1996 and 2000.
Studies for the ‘post-NCRN’ period included studies in the
NCRN Portfolio Database that closed to recruitment in 2005, 2006
or 2007 and had been funded by Cancer Research UK, the Medical
Research Council or Department of Health. This identified 40
studies, of which nine recruited most patients from non-UK sites
and were excluded. The post-NCRN group included 31 RCTs.
Factors analysed included whether or not studies met their
planned recruitment target, and whether or not the speed of trial
recruitment was greater after NCRN.
RESULTS
Data are presented on the national portfolio of cancer research
studies and accrual for the period 1 April 2001 to 31 March 2008,
and on the impact of the NCRN on study delivery.
Portfolio development
The NCRN portfolio was established to maximise the impact of the
NCRN in improving patient care by ensuring that NCRN
infrastructure was used to support high-quality research relevant
to the needs of the NHS. It incorporates all larger Phase II and
Phase III trials, together with other well-designed studies, that were
funded by the NIHR and its partners, plus a number of other
studies (e.g., international studies). In 2005, the NCRN’s remit was
extended to include industry-funded studies.
To ensure the development of nationwide portfolios, several
UK-wide Clinical Studies’ Groups were established, in some cases
building on existing structures. Each Group has multidisciplinary
scientific members, patient/public representatives and funding
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body representatives. The Groups have a central role in the
development and oversight of a balanced national portfolio and are
the preferred, and in practice now often the primary, route for
study development. The Clinical Studies’ Groups focus either on
specific cancer types or on generic groups, for example, primary
care. All proposed studies emerging from these groups are still
required to secure their research funding via the usual competitive
routes before they can open within the NCRN portfolio.
The number of studies has more than doubled since NCRN was
established, with a steady growth in both randomised and non-
randomised studies. Table 1 shows the number of studies open to
recruitment or in set-up in each financial year.
Accrual
Overall accrual The initial target of doubling the number of adult
cancer patients entered into clinical research studies in England
within 3 years was met ahead of schedule. Figure 1 shows the total
annual NCRN UK accrual. Collection of accrual data for other
recruits (i.e., not cancer patients) into screening and prevention
studies was not done routinely until 2004/5.
Accrual of cancer patients increased steadily in the first 5 years,
with increased recruitment to both randomised and non-
randomised studies. Although there has been a slowing in the
rate of increase in recruitment since 2005/6 in terms of cancer
patients, significant NCRN resources are now being used in
screening and prevention studies with over 43 000 other indivi-
duals being recruited to these studies in 2007/8. *Web link to
detailed data in Appendix Table A1.
Recruitment by Local Research Network varied considerably.
Figure 2 presents the percentage accrual incidence for each of the
34 Local Research Networks in England for 2001/2 and 2007/8. We
explored whether the type of Network affected the level of activity
by clustering Networks according to the presence of major
teaching or research centres, the resources available outside
NCRN funding, the size of the Network, the number and type of
NHS Trusts in the Network and the presence of a wider research
infrastructure, but found no evidence of different impacts.
In 2001/2, only two Local Research Networks recruited the
NCRN target of 7.5% of incident patients, and only one Network
recruited more than 10% of patients. By 2007/8, almost every
Network had reached the target of 7.5%, with over half of the
Networks (18/32) entering more than 10% of patients into high-
quality cancer research studies.
Patient accrual increased for nearly all cancer types, including
common and less common cancers. In 2001/2, only six patients
with head and neck cancer were recruited into high-quality
national studies, compared with 163 in 2007/8. Recruitment in
breast cancer increased from 4011 patients in 2001/2 to 11 401
patients in 2007/8.
More clinical sites were involved in cancer research through
NCRN, demonstrating increased access to studies for patients.
Across the United Kingdom, 66 Trusts have radiotherapy facilities
and these centres generally provide expertise in the management
of all cancers within their immediate geographical locality and of
less common cancers referred from other hospitals. There was an
overall increase in recruitment from all centres; recruitment from
centres with radiotherapy facilities doubled and recruitment
from centres without radiotherapy facilities almost quadrupled.
The centres without radiotherapy facilities, generally district
hospitals, are now collectively contributing almost half of the
patients entered into all NCRN studies, demonstrating wider
participation in research studies as a result of the NCRN support.
Recruitment into studies that closed before and after
NCRN was established
Proportion that achieved the recruitment target Figure 3 shows
the proportion of studies that met the recruitment target
(irrespective of time frames) for the subsets of studies that closed
before and after NCRN was established. In all, 17 of 28 studies
(61%) closing before NCRN was established did not meet
their recruitment target. Of these 17 studies, 7 recruited 490%,
4 recruited 50–80% and 6 recruited o20% of the planned target.
In comparison, only 8 of 31 studies (26%) closing after the
establishment of NCRN did not meet their planned recruitment
target. Of these eight studies, one recruited 490%, one recruited
50–80%, four recruited 20–49% and two recruited o20% of the
Table 1 Numbers of UK cancer studies open to recruitment or in set-up in each financial year
2001/02 2002/03 2003/04 2004/05 2005/06 2006/07 2007/08
Total number of studies 182 240 304 337 368 414 451
Number of randomised studies 124 152 184 197 217 252 271
Number of non-randomised studies 58 88 120 140 151 162 180
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Local Research Network (LRN) in England for 2001/2 and 2007/8.
Strengthening clinical cancer research
M Stead et al
1531
British Journal of Cancer (2011) 104(10), 1529 – 1534& 2011 Cancer Research UK
C
li
n
ic
a
l
S
tu
d
ie
s
planned target. After NCRN was established, 29% of studies met
the recruitment target ahead of schedule, compared with only 3%
of studies that closed before NCRN was established.
Speed of recruitment. Figure 4 shows that the median actual
recruitment period for studies that closed before NCRN was
established was longer than the planned period, by an average
of 7 months, whereas the median actual recruitment for studies
in the post-NCRN period was the same as the planned recruit-
ment period.
Comparison of sample sizes and actual number of patients
recruited. Figure 5 shows the median planned recruitment
figures compared with the median actual recruitment figures for
studies closing before NCRN was established and for studies
closing after NCRN was established.
Figure 5 shows that, on average, the number of patients
recruited to studies in the pre-NCRN period was significantly less
than the planned sample size, but after NCRN was established,
target sample sizes were usually met.
The data in Figures 3–5 show a general trend towards
improvement in terms of delivery of cancer research studies.
DISCUSSION
The coordinated and managed approach to clinical research
described here has demonstrated increased accrual and faster trial
delivery, which should improve outcomes and care. The United
Kingdom accrual of cancer patients to clinical studies has
increased since the establishment of NCRN, with almost 32 000
(12% of annual incident cases) cancer patients recruited in 2007/8
compared with 27 012 patients entering into similar National
Cancer Institute US studies in October 2006–September 2007 and
with 5473 patients entering into European Organisation for
Research and Treatment of Cancer studies in 2007. Having a clear
national target provided a focus for the delivery of studies in a
short period of time.
Integration of the Research Networks with the Cancer Service
Networks from NCRN’s initiation provided a structure for
collaborative working and placed clinical research on the agenda
of service provision. The provision of over 700 dedicated and
funded personnel focussing on the support and delivery of
cancer clinical research has also contributed to the success of the
NCRN. National coordination of the research support staff
streamlined and standardised human resources systems such as
job descriptions and provided consistent high-quality training and
development.
The portfolio has grown in nearly all cancers, with increases in
both randomised and non-randomised studies. Although the
portfolio now includes more screening and prevention studies
and more genetic epidemiology studies, the majority of studies
remain interventional drug trials, and ongoing work is needed to
encourage the development of other types of interventional study,
such as new medical devices, surgical and radiotherapeutic
techniques. The success of the NCRN approach to support clinical
cancer research suggests that this coordinated and resourced
enhancement in recruitment could be harnessed to preferentially
support portfolio development and recruitment into non-drug
trials and rare cancer sites, although not withdrawing support
from important studies in the more common cancers. Future
Pre-NCRN
Post-NCRN
Proportion of studies that
met recruitment target
ahead of schedule (3%)
Proportion of studies that
met recruitment target on
schedule or longer (36%)
Proportion of studies that
did not meet recruitment
target (61%)
Proportion of studies that
met recruitment target
ahead of schedule (29%)
Proportion of studies that
met recruitment target on
schedule or longer (45%)
Proportion of studies that
did not meet recruitment
target (26%)
Figure 3 Proportion of studies meeting the study’s recruitment target.
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developments of the NCRN are to move towards a more balanced
portfolio in terms of common and rare cancers, drug and non-drug
trials, and academic or commercially sponsored studies.
Increases in accrual across the whole of the United Kingdom
demonstrate a broadening of access to research studies, with
patients more often being able to enter studies at their local
hospital, whether or not it is a teaching hospital, facilitating
recruitment across the whole of the country and thus reducing
geographical inequalities in access to clinical research.
In 2001/2, only two Local Research Networks recruited more
than 7.5% of patients. By 2007/8, almost every Network had
reached the target of 7.5% of patients, with over half of the
Networks recruiting more than 10% of patients. We explored
whether the type of Network affected the level of activity, but
found no consistent pattern; this target was reached ahead of
schedule and indeed exceeded, demonstrating that a coordinated
and targeted effort can result in increased recruitment, geo-
graphically broader trial participation and timely delivery of
research studies, while maintaining high standards of research
quality. Cancer patient outcomes improved steadily during the
implementation of the NCRN (Rachet et al, 2009), but it is too
early to determine how much NCRN contributed to this. The
anticipated contribution will depend on the implementation of
positive trial results and probably on increased participation
(du Bois et al, 2005; Majundar et al, 2008) and the number of
hospitals participating in cancer clinical research.
We believe that the use of this simple target, combined with
the commitment, drive and motivation of the Clinical Lead,
the Research Network Manager and the clinicians, and
research support staff within the Network, encouraged broad
support from the local NHS leading to increases in the levels of
research activity.
Although recruitment increased steadily in the first 5 years of
NCRN, the rate of growth has slowed in the past 2 years. This is
likely to be due to a number of factors, including networks
reaching saturation point with their current resources. Increasing
numbers of patients are on follow-up (estimated to be 84 000
patients in 2006/7), placing an increased burden on the networks.
In addition, the EU Directive for Clinical Trials was translated into
UK Law in 2004 and resulted in trials of medicinal products taking
longer to open as a result of increased regulatory approvals and
documentation and uncertainty about different elements of its
implementation (Hearn and Sullivan, 2007).
As well as increasing the levels of activity and broadening study
participation, study delivery has improved. More studies open to
recruitment during NCRN met the recruitment target – 74%
compared with 39% for studies closing before NCRN was
established. This is also higher than that noted in a review of
trials that had started in or after 1994 and were due to end before
2003, where only 31% of the 114 RCTs funded by the Medical
Research Council or Health Technology Assessment Programmes
in a range of diseases recruited successfully (Campbell et al, 2007).
After the establishment of NCRN, recruitment to time and target
was achieved more often. These data suggest a trend towards
improvement in terms of delivery of cancer research studies,
although there is still scope for improvement in individual studies.
The success of NCRN has been a major driver in the
establishment of the NIHR Clinical Research Network, which aims
to support all areas of clinical research, including industry-funded
commercial trials, and to facilitate the conduct of trials and other
well-designed studies across the United Kingdom. The Department
of Health is investing in improving the research management and
governance procedures to speed up the approval of studies.
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APPENDIX
Table A1 Detailed annual accrual of cancer patients into NCRN portfolio studies
All 2001/02 2002/03 2003/04 2004/05 2005/06 2006/07 2007/08
Cancer Total Total Total Total Total Total Total
Randomised 8141 10 419 12 392 13 166 10 801 9728 11 079
Non-randomised 1943 2722 9470 10 587 15 183 16 787 16 357
England total 10 084 13 141 21 862 23 753 25 984 26 515 27 436
Randomised 43 172 83 69 95
Non-randomised 19 119 169 166 113
Northern Ireland total 62 291 252 235 208
Randomised 134 279 901 1151 1136 1241 1111
Non-randomised 0 19 331 256 796 600 676
Scotland total 134 298 1232 1407 1932 1841 1787
Randomised 118 243 594 586 602 592 808
Non-randomised 20 97 277 226 1017 1095 1525
Wales total 138 340 871 812 1619 1687 2333
NCRN total Randomised 8161 10 941 13 930 15 075 12 622 11 630 13 093
Non-randomised 2195 2838 10 097 11 188 17 165 18 648 18 671
NCRN total 10 356 13 779 24 027 26 263 29 787 30 278 31 764
Abbreviation: NCRN¼National Cancer Research Network.
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